BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia

Molecular Cancer Therapeutics

Volumn 12, Issue 12, 2013, Pages 2940-2949

  Pierceall, William E ^a   Kornblau, Steven M ^b,c   Carlson, Nicole E ^a   Huang, Xuelin ^d   Blake, Noel ^a   Lena, Ryan ^a   Elashoff, Michael ^a   Konopleva, Marina ^b,c   Cardone, Michael H ^a   Andreeff, Michael A ^b,c  

^a Eutropics Pharmaceuticals   (United States)

^b Department of Stem Cell Transplantation ^*  (United States)

^c Division of Cancer Medicine   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BH3 PROTEIN; BIM PROTEIN; BMF PROTEIN; CYTARABINE; FLT3 LIGAND; FLUDARABINE; HRK PROTEIN; MEMBRANE PROTEIN; PROTEIN BAD; PROTEIN BCL 2; PROTEIN NOXA; PUMA PROTEIN; PUMA2A PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER PATIENT; CANCER SURVIVAL; CELL MITOCHONDRIAL DEPOLARIZATION; CONTROLLED STUDY; CYTOGENETICS; DEPOLARIZATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BIOLOGICAL MARKERS; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; REMISSION INDUCTION; ROC CURVE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890484192     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0692     Document Type: Article

References (28)

1. NCI cancer statistics. Available from: www.cancer.gov/cancertopics/types/ leukemia
2. American Cancer Society: Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society, 2013. Available from: http://www.cancer.org/research/ cancerfactsfigures/cancerfactsfigures/cancerfacts-figures-2013 (Accessed May 2, 2013).
3. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997;24:57-69.
4. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
5. Baldus CD, Mrózek K, Marcucci G, Bloomfield CD. Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: A concise review. Br J Haematol 2007;137:387-400.
6. Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 2001;20:5660-79.
7. KornblauSM, Tibes R, Qiu Y, Chen W, Kantarjian HM, Andreeff M, et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009;113:154-64.
8. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, Covey T, et al. Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res 2010;16:3721-33.
9. Wuchter C, Karawajew L, Ruppert V, Schrappe M, Harbott J, Ratei R, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of Pglycoprotein function, maturation stage, and cytogeneticis. Leukemia 1999;13:1943-53.
10. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998;91:991-1000.
11. Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, et al. The prognostic impact of BCL-2 protein expression in acute myelogemous leukemia varies with cytogenetics. Clin Cancer Res 1999;5:1758-66.
12. Danna EA, Nolan GP. Transcending the biomarker mindset: deciphering disease mechanisms at the single-cell level. Curr Opin Chem Biol 2006;10:20-7.
13. Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, Putta S, et al. Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS ONE 2010;5:e13543.
14. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-85.
15. Letai A. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008;8:121-32.
16. Ryan JA, Brunelle JK, Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4 CD8 thymocytes. Proc Natl Acad Sci U S A 2010;107:12895-900.
17. Weinstein B, Joe A. Oncogene addiction. Cancer Res 2008;68: 3077-80.
18. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006;9:351-65.
19. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117:112-21.
20. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011;334: 1129-33.
21. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012;151: 344-55.
22. Kornblau SM, Qui YH, Zhang N, Singh N, Faderi S, Ferrajoli A, et al. Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia. Blood 2011;118:5604-12.
23. Tibes R, Qiu YH, Lu Y, Hennessey B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoetic stemcells (HSC). Mol Cancer Ther 2006;5:2512-21.
24. Hunyady B, Krempels K, Harta G, Mezey E. Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem 1996;44: 1353-62.
25. Zhang W,Konopleva M,Ruvolo VR, McQueen T, Evan RL, Bomman WG, et al. Sorafenib induces apoptosis of AML cells via BIM-mediated activation of the intrinsic apoptosis pathway. Leukemia 2008;22:808-18.
26. Zhang W, Konopleva M, Burks JK, Dywer KC, Schober WD, Yang JY, et al. Blockade of mitogen-activated protein kinase/extracellular signal-related kinase kinase and murine double minute synergistically induces apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res 2010;70:2424-34.
27. Nordigarden A, Kraft M, Elliasson P, Labi V, Lam EW, Villunger A, Jonsson AI. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoetic progenitors carrying oncogeneic FLT3. Blood 2009;113:2302-11.
28. Grocek E, Wang X, Liu X, Liu CG, Studzinski GP. MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res 2011;71:6230-9.